Heartseed Inc.
Heartseed is a Tokyo-based regenerative-medicine company listed on the TSE Growth market (219A). Its lead programme HS-001, a cell therapy for heart failure, is in the Phase 1/2 LAPiS study in Japan.
| Headquarters | Tokyo, Japan |
|---|---|
| Listing | TSE Growth:219A |
| Lead asset / stage | HS-001 Phase 1/2 — Japan (LAPiS study) |
| Latest event | Heartseed received the Emerging Biotech Company award at the BioSpectrum Asia Excellence Awards 2026. |